Upstream regulator pathway analysis in tumors from AA patients compared with EA patients showed decreased signaling in progestin-associated targets such as AR, the androgen receptor, consistent with the hormonally responsive breast and gynecologic tumors included in this cohort (Fig. 1D). The gene discussed is AR; the disease is female reproductive system neoplasm.